Vosevi (sofosbuvir/velpatasvir/voxilaprevir) — Medica
Chronic Hepatitis C Virus (HCV) Genotype 1a or 3 infection with prior NS5A inhibitor- or sofosbuvir-based regimen failure
Initial criteria
- age ≥ 18 years
- Patient does not have cirrhosis OR has compensated cirrhosis (Child-Pugh A)
- Patient had a prior null response, prior partial response, or relapse after prior treatment with an HCV direct-acting antiviral regimen containing an NS5A inhibitor OR with a sofosbuvir-containing regimen plus a non-NS5A inhibitor (e.g., Sovaldi + ribavirin ± pegylated interferon OR Sovaldi + an NS3 inhibitor such as Olysio, Victrelis, or Incivek)
- Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
Approval duration
12 weeks